In the 2012 ESC guidelines for the management of heart failure, various gaps in the clinical evidence base were identified. Four studies published in 2012 go some way to resolving this data deficit, and treatment recommendations can now be updated accordingly.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
McMurray, J. J. V. et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology: developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur. J. Heart Fail. 14, 803–869 (2012).
Homma, S. et al. Warfarin and aspirin in patients with heart failure and sinus rhythm. N. Engl. J. Med. 366, 1859–1869 (2012).
Bart, B. A. et al. Ultrafiltration in decompensated heart failure with cardiorenal syndrome. N. Engl. J. Med. http://dx.doi.org/10.1056/NEJMoa1210357.
Shah, R. V., Desai, A. S. & Givertz, M. M. The effect of renin–angiotensin system inhibitors on mortality and heart failure hospitalization in patients with heart failure and preserved ejection fraction: a systematic review and meta-analysis. J. Card. Fail. 16, 260–267 (2010).
Ruilope, L. M. et al. Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study. Lancet 375, 1255–1266 (2010).
Solomon, S. D. et al. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet 380, 1387–1395 (2012).
Desai, A. S. et al. Rationale and design of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial: a randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction. Am. Heart J. 162, 966–972 (2011).
Teerlink, J. R. et al. Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study. Lancet 373, 1429–1439 (2009).
Teerlink, J. R. et al. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. Lancet http://dx.doi.org/10.1016/S0140-6736(12)61855-8.
Author information
Authors and Affiliations
Ethics declarations
Competing interests
A. A. Voors has received consultancy fees, research grants, or both from the following companies/organisations: Alere, Bayer, Cardio3 BioSciences, Celladon, Ceva, Dutch Heart Foundation, European Commission, Novartis, Servier, Torrent, and Vifor. Additionally, A. A. Voors was a member of the committee for the 2012 ESC guidelines on heart failure, and a member of the steering committees of PARAMOUNT and the RELAX AHF trial.
Rights and permissions
About this article
Cite this article
Voors, A. Trial data resolve gaps in evidence-based treatment. Nat Rev Cardiol 10, 67–68 (2013). https://doi.org/10.1038/nrcardio.2012.190
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrcardio.2012.190
